Advancing Cardiac Amyloidosis Care Through Insights from Cardiopulmonary Exercise Testing
Authors:
- Pietro PugliattiPPPietro Pugliatti
- Giancarlo TrimarchiGiancarlo Trimarchi
- Federico BarocelliFBFederico Barocelli
- Fausto PizzinoFausto Pizzino
- Francesco Di SpignoFSFrancesco Di Spigno
- Andrea TedeschiATAndrea Tedeschi
- Maurizio Cusmà PiccioneMPMaurizio Cusmà Piccione
- Pierangela IrreraPIPierangela Irrera
- Daniela AschieriDADaniela Aschieri
- Giampaolo NiccoliGiampaolo Niccoli
- Umberto ParadossiUmberto Paradossi
- Gianluca Di BellaGBGianluca Di Bella
Open Access
- 29 November 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (23) , 7285
Abstract
Cardiac amyloidosis, encompassing both transthyretin (ATTR) and light-chain (AL) types, poses considerable challenges in patient management due to its intricate pathophysiology and progressive course. This narrative review elucidates the pivotal role of cardiopulmonary exercise testing (CPET) in the assessment of these patients. CPET is essential for evaluating disease progression by measuring cardio-respiratory performance and providing prognostic insights. This functional test is crucial not only for tracking the disease trajectory, but also for assessing the effectiveness of disease-modifying therapies. Moreover, CPET facilitates the customization of therapeutic strategies based on individual patient performance, enhancing personalized care. By objectively measuring parameters such as peak oxygen uptake (VO2 peak), ventilatory efficiency, and exercise capacity, clinicians can gain a deeper understanding of the degree of functional impairment and make informed decisions regarding treatment initiation, adjustment, and anticipated outcomes. This review emphasizes the importance of CPET in advancing personalized medicine approaches, ultimately striving to improve the quality of life and clinical outcomes for patients with cardiac amyloidosis.Keywords
This publication has 110 references indexed in Scilit:
- Amyloid Neuropathy: From Pathophysiology to Treatment in Light‐Chain Amyloidosis and Hereditary Transthyretin AmyloidosisAnnals of Neurology, 2024
- Cardiopulmonary Exercise Testing in Evaluating Transthyretin AmyloidosisJAMA Cardiology, 2024
- A New Staging System Using Right Atrial Strain in Patients with Immunoglobulin Light-Chain Cardiac AmyloidosisESC Heart Failure, 2024
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- Cardiopulmonary Exercise Testing Predicts Prognosis in Amyloid Cardiomyopathy: A Systematic Review and Meta-AnalysisESC Heart Failure, 2023
- Peak O2-Pulse Predicts Exercise Training-Induced Changes in Peak V̇O2 in Heart Failure with Preserved Ejection FractionESC Heart Failure, 2022
- All-Cause Mortality Predicted by Peak Oxygen Uptake Differs Depending on Spirometry Pattern in Patients with Heart Failure and Reduced Ejection FractionESC Heart Failure, 2021
- Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosisEuropean Journal of Heart Failure, 2020
- Inotropic Myocardial Reserve Deficiency is the Predominant Feature of Exercise Haemodynamics in Cardiac AmyloidosisEuropean Journal of Heart Failure, 2017
- A case of cardiac amyloidosis presenting with symptoms of exertional syncopeClinical Cardiology, 1991